New therapies for neuromyelitis optica spectrum disorder
Journal: The Lancet Neurology; November 10, 2020
Author(s): Michael Levy, Kazuo Fujihara and Jacqueline Palace
New therapies for NMOSD
Three therapies have recently been approved for neuromyelitis optica spectrum disorder (NMOSD): eculizumab, satralizumab, and inebilizumab. Four randomised controlled trials have tested the efficacy of these three new therapies and have shown a benefit in preventing future attacks. Efficacy, safety, tolerability, and practical considerations, including potential cost, differ for each drug and might affect the rate of use in real-world populations of patients with neuromyelitis optica spectrum disorder. Nevertheless, compared to the typical situation for rare diseases, these approved therapies represent an abundance of treatment options for NMOSD patients.
Free Access: Abstract only
